Quest Partners LLC Boosts Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Quest Partners LLC increased its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 253.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,378 shares of the company’s stock after acquiring an additional 7,440 shares during the quarter. Quest Partners LLC’s holdings in ORIC Pharmaceuticals were worth $73,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its position in shares of ORIC Pharmaceuticals by 104.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 12,922 shares of the company’s stock worth $178,000 after purchasing an additional 6,617 shares in the last quarter. ProShare Advisors LLC acquired a new position in ORIC Pharmaceuticals during the first quarter worth approximately $161,000. Vanguard Group Inc. lifted its stake in ORIC Pharmaceuticals by 27.9% in the first quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock valued at $39,628,000 after buying an additional 629,536 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of ORIC Pharmaceuticals by 140.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock valued at $21,543,000 after acquiring an additional 915,175 shares during the period. Finally, NEA Management Company LLC purchased a new position in shares of ORIC Pharmaceuticals during the first quarter worth approximately $20,625,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Price Performance

ORIC opened at $10.10 on Wednesday. ORIC Pharmaceuticals, Inc. has a 12 month low of $5.27 and a 12 month high of $16.65. The stock has a market capitalization of $712.45 million, a P/E ratio of -5.61 and a beta of 1.12. The business has a 50 day simple moving average of $9.98 and a 200-day simple moving average of $10.04.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.78 EPS for the current year.

Analysts Set New Price Targets

ORIC has been the subject of a number of recent research reports. Oppenheimer decreased their price target on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Stifel Nicolaus began coverage on ORIC Pharmaceuticals in a report on Friday, September 6th. They set a “buy” rating and a $20.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Wednesday, August 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $18.00.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.